HIV status may affect the progression of HPV infection to cervical pre-cancer

June 1, 2017

A study of Senegalese women showed that human papillomavirus (HPV) infection was more likely to develop into cervical pre-cancer in women living with human immunodeficiency virus.

The study is published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, by Hilary K. Whitham, PhD, MPH, a research associate at the University of Minnesota in Minneapolis.

While most HPV infections are cleared by the body's immune system, persistent HPV can lead to the development of and . Previous research has indicated that HIV-positive women face an increased risk of HPV infection, precancerous lesions, and cervical compared with HIV-negative women.

In order to increase understanding of the way HPV infection progresses, and to compare its progression in HIV-negative and HIV-positive women, Whitham and colleagues analyzed data from six studies conducted from 1994 to 2010 in Senegal, where HIV is endemic. They followed 1,320 women for an average of two years, testing them for HPV and cervical abnormalities approximately every four months. At each clinic visit, women were characterized as normal, HPV-positive, or HSIL (HPV-positive with high-grade squamous intraepithelial lesions, a precancerous lesion that may progress to cervical cancer if untreated).

The study showed that HIV-positive women had higher rates of acquiring HPV, and lower rates of clearing HPV infection, than HIV-negative women.

Women whose immune systems were compromised by HIV were also more likely to have HPV infection progress to pre-cancer, the study indicated. For instance, HIV-positive women were 2.55 times more likely to have their HPV infection progress to HSIL than HIV-negative women. Whitham explained that as HIV ravages the body's immune system, "HPV goes unchecked, replicating quickly and developing abnormal lesions which can progress to cancer."

"The study suggests that in countries like Senegal in West Africa, where cervical cancer screening is not widely available, HIV-positive women may benefit from targeted cervical cancer prevention efforts," Whitham said.

"In areas where cervical cancer screening is not widely available and HIV prevalence is high, these findings highlight that targeted screening of the high-risk HIV-positive population may provide an important step in cervical cancer prevention," Whitham said. "These results also highlight that HPV vaccination of young women prior to HIV infection is an important preventive measure."

Whitham said she expects that the results of this study would be similar in women from other countries, especially other sub-Saharan African nations with high HIV rates. However, she said, further studies would be required to confirm the findings and to account for behavioral differences between populations such as smoking, birth control use, and age at first sexual activity.

Whitham said a limitation of the study is that much of the data predated the widespread use of anti-retroviral therapy, which limited the researchers' capacity to analyze the effects of those treatments on HPV progression. She added that as HIV-positive now live longer due to anti-retroviral therapy, they may face further increased risk of cervical cancer due to additional time to acquire HPV and for pre-cancerous lesions to progress to cervical cancer. This highlights the importance of developing cervical cancer prevention strategies in areas where HIV is endemic, Whitham said.

Explore further: Women should continue cervical cancer screening as they approach age 65

Related Stories

Women should continue cervical cancer screening as they approach age 65

May 1, 2017
Cervical cancer is often thought of as a disease that primarily affects young women. Because of this, many older women fail to keep up with appropriate screening as they age. While current guidelines indicate that screening ...

Screening, HPV vaccine can prevent cervical cancer: FDA

February 8, 2017
(HealthDay)—Women can reduce their risk of cervical cancer through vaccination and screening, the U.S. Food and Drug Administration says.

Most anal lesions don't cause cancer in men, research shows

March 23, 2012
(HealthDay) -- Anal human papillomavirus (HPV) infection and precancerous lesions are common among gay and bisexual men, but most of these cases will not progress to anal cancer, a new analysis of earlier research shows.

Low incidence of cervical cancer, CIN3+ for HPV-negative women

October 7, 2016
(HealthDay)—Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+), which supports an extension of the cervical screening ...

Highly effective cervical cancer screening for low income countries

March 3, 2017
Cervical cancer is the second most common cancer in women in developing countries, and globally some quarter of a million women die from the disease each year - most of them from low and middle income countries (LMICs).

Study finds decreased rates of high-grade cervical lesions in young women

June 22, 2015
A new analysis indicates that rates of high-grade cervical lesions decreased in young U.S. women after vaccines were made available to protect against human papillomavirus (HPV), but the trend may be due in part to changes ...

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.